The Intersection of Cellular and Systemic Metabolism: Metabolic Syndrome in Systemic Lupus Erythematosus.
Morgan TerrellLaurence M MorelPublished in: Endocrinology (2022)
A high prevalence of metabolic syndrome (MetS) has been reported in multiple cohorts of systemic lupus erythematosus (SLE) patients, most likely as one of the consequences of autoimmune pathogenesis. Although MetS has been associated with inflammation, its consequences on the lupus immune system and on disease manifestations are largely unknown. The metabolism of immune cells is altered and overactivated in mouse models as well as in patients with SLE, and several metabolic inhibitors have shown therapeutic benefits. Here we review recent studies reporting these findings, as well as the effect of dietary interventions in clinical and preclinical studies of SLE. We also explore potential causal links between systemic and immunometabolism in the context of lupus, and the knowledge gap that needs to be addressed.
Keyphrases
- systemic lupus erythematosus
- metabolic syndrome
- disease activity
- end stage renal disease
- ejection fraction
- healthcare
- mouse model
- insulin resistance
- newly diagnosed
- chronic kidney disease
- oxidative stress
- rheumatoid arthritis
- uric acid
- case control
- prognostic factors
- multiple sclerosis
- peritoneal dialysis
- type diabetes
- drug induced
- risk assessment
- cell therapy
- skeletal muscle
- electronic health record